These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31307348)

  • 21. Democrats prioritize pricing, generics and drug safety.
    Fox JL
    Nat Biotechnol; 2007 Feb; 25(2):150-1. PubMed ID: 17287735
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmaceuticals and medical devices: cost savings. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
    [No Abstract]   [Full Text] [Related]  

  • 23. Does public perception bias lead to more frequent reporting of adverse events: branded vs generic drugs.
    Qian J; Mishuk AU; Hansen RA
    Expert Opin Drug Saf; 2018 Aug; 17(8):753-756. PubMed ID: 30052091
    [No Abstract]   [Full Text] [Related]  

  • 24. Federal government will not challenge state laws on marijuana.
    Dyer O
    BMJ; 2013 Sep; 347():f5437. PubMed ID: 24005057
    [No Abstract]   [Full Text] [Related]  

  • 25. Impossible? Outlawing state safety laws for generic drugs.
    Glantz LH; Annas GJ
    N Engl J Med; 2011 Aug; 365(8):681-3. PubMed ID: 21830958
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmaceuticals: generic/ therapeutic drug substitution: year end report-2002.
    Floridi T; Kammer C
    Issue Brief Health Policy Track Serv; 2002 Dec; ():1-12. PubMed ID: 12856672
    [No Abstract]   [Full Text] [Related]  

  • 27. The impact of Wyeth v. Levine on FDA regulation of prescription drugs.
    Ausness RC
    Food Drug Law J; 2010; 65(2):247-83, i-ii. PubMed ID: 24475542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA weighs communicating drug-related risk to patients.
    Stephenson J
    JAMA; 1999 Aug; 282(6):515. PubMed ID: 10450699
    [No Abstract]   [Full Text] [Related]  

  • 29. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
    Smirniotopoulos A
    Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behind Schedule - Reconciling Federal and State Marijuana Policy.
    Haffajee RL; MacCoun RJ; Mello MM
    N Engl J Med; 2018 Aug; 379(6):501-504. PubMed ID: 29996065
    [No Abstract]   [Full Text] [Related]  

  • 31. Cooking up solutions to a cooked up menace: responses to methamphetamine in a federal system.
    Harv Law Rev; 2006 Jun; 119(8):2508-29. PubMed ID: 16827221
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA moves closer to new requirements for NTI drugs.
    Traynor K
    Am J Health Syst Pharm; 2011 Sep; 68(17):1568-9, 1570. PubMed ID: 21856797
    [No Abstract]   [Full Text] [Related]  

  • 33. Enforcing Federal Drug Laws in States Where Medical Marijuana Is Lawful.
    Gostin LO; Hodge JG; Wetter SA
    JAMA; 2018 Apr; 319(14):1435-1436. PubMed ID: 29582074
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety of newly approved drugs: implications for prescribing.
    Temple RJ; Himmel MH
    JAMA; 2002 May; 287(17):2273-5. PubMed ID: 11980528
    [No Abstract]   [Full Text] [Related]  

  • 35. 2004: a federal and state health odyssey.
    Wakefield MK
    Nurs Econ; 2004; 22(1):47-8. PubMed ID: 15000051
    [No Abstract]   [Full Text] [Related]  

  • 36. Primum non nocere.
    Gifford RW
    JAMA; 1977 Aug; 238(7):589-90. PubMed ID: 577959
    [No Abstract]   [Full Text] [Related]  

  • 37. A deserving role for the National Center for Advancing Translational Sciences.
    Gurwitz D; Lunshof JE
    Lancet; 2011 May; 377(9779):1745-6. PubMed ID: 21601704
    [No Abstract]   [Full Text] [Related]  

  • 38. US court rules that patients harmed by generic drugs cannot claim damages.
    Dyer C
    BMJ; 2011 Jun; 342():d4079. PubMed ID: 21715458
    [No Abstract]   [Full Text] [Related]  

  • 39. States and US Government spar over medical marijuana.
    Furlow B
    Lancet Oncol; 2012 May; 13(5):450. PubMed ID: 22701888
    [No Abstract]   [Full Text] [Related]  

  • 40. The Vernacular of Risk--Rethinking Direct-to-Consumer Advertising of Pharmaceuticals.
    Greene JA; Watkins ES
    N Engl J Med; 2015 Sep; 373(12):1087-9. PubMed ID: 26287749
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.